Introduction The emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants has caused unprecedented health and socioeconomic crises, necessitating …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global
pandemic of novel coronavirus disease (COVID-19). The neutralizing monoclonal …

Emerging severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants,
especially the Omicron variant, have impaired the efficacy of existing vaccines and most …

The game between therapeutic monoclonal antibodies (mAbs) and continuously emerging
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has favored the …

Dear Editor, The ongoing coronavirus disease 2019 (COVID-19) pandemic is a serious
public health crisis, which is caused by severe acute respiratory syndrome coronavirus 2 …

Rapid emergence of new variants of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has prompted an urgent need for the development of broadly applicable and …

Monoclonal antibodies are a promising approach to treat COVID-19, however the
emergence of SARS-CoV-2 variants has challenged the efficacy and future of these …

The emergence of SARS-CoV-2 variants that threaten the efficacy of existing vaccines and
therapeutic antibodies underscores the urgent need for new antibody-based tools that …

New threats posed by the emerging circulating variants of SARS-CoV-2 highlight the need to
find conserved neutralizing epitopes for therapeutic antibodies and efficient vaccine design …

The devastating impact of COVID-19 on global health shows the need to increase our
pandemic preparedness. Recombinant therapeutic antibodies were successfully used to …